This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Sorrento Therapeutics (SRNE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Sorrento Therapeutics (SRNE) have performed compared to their sector so far this year.
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 11.28% and 2.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of -10.71% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug
by Zacks Equity Research
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
Immatics (IMTX) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -18.28% and 23.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -51.61% and 70.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 0% and 56.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?